Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival.
Recent studies suggest that cyclooxygenese-2 (COX-2) enzyme activation may play a role in hepatocarcinogenesis. However, the clinical significance of COX-2 expression in hepatocellular carcinoma (HCC) remains obscure. This study evaluated COX-2 expression in hepatitis B and hepatitis C virus related HCC and in HCC patients with an unknown etiology. Liver tissue samples of 31 patients with HCC (27 men and 4 women; age range, 48-75 years) were analyzed. COX-2 expression was evaluated by immunohistochemically in the tumor tissues. Patient data including age, sex, Child score, stage, grade of the tumor and survival were analyzed. Of these patients 19 were positive for hepatitis B virus (HBV), 6 were positive for hepatitis C virus (HCV) and 6 patients were negative for all viral markers and other etiologic factors. COX-2 staining were evaluated in 2 groups (group 1: COX-2 expression less than 25% (grades 1-2 COX-2 expression), and group 2: Cox-2 expression 25% or more (grades 3-5 COX-2 expression). COX-2 expression was shown in all HCC samples with positive or negative viral markers. No difference was found between degree of COX-2 expression and the etiology of HCC. COX-2 expression was not correlated with number of lesion or stage of the disease or grade of the tumor. COX-2 expression was not related with Child score of the patients. Median survival of all patients was 32 months. Median survival of patients did not differ according to patient's viral marker status. No difference was observed in median survival of patients in group 1 and 2. As a result, COX-2 system seem to be shared part in hepatocarcinogenesis regardless factors that initiate the disease. Although COX-2 expression appears to be independent of disease's characteristics', treatments that target this system appear to be feasible in the management of HCC.
Yildirim
Yesim
Y
Department of Medical Oncology, Faculty of Medicine, Baskent University, Fevzi Cakmak Caddesi 12. Sokak 7/5 TR 06490 Bahcelievler, Ankara, Turkey. dryesimyildirim@yahoo.com
Ozyilkan
Ozgur
O
Bilezikci
Banu
B
Akcali
Zafer
Z
Haberal
Mehmet
M
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000201:enzymology* / Q000401:mortality / Q000821:virology; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D006509:Hepatitis B / Q000150:complications / Q000473:pathology / Q000821:virology; D006515:Hepatitis B virus / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications / Q000473:pathology / Q000821:virology; D006801:Humans; D007124:Immunoenzyme Techniques; D008113:Liver Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000821:virology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human